By Fineline Cube Junshi Biosciences (HKG: 1877, SHA: 688180) announced that the National Medical Products Administration (NMPA) has accepted its supplemental application for an expanded indication of toripalimab injection (Loqtorzi), its self-developed anti-PD-1 monoclonal antibody. The application seeks approval for perioperative treatment with toripalimab in combination with platinum-containing chemotherapy, followed by toripalimab monotherapy as adjuvant therapy, for adult patients with resectable Stage II–III non-small cell lung cancer (NSCLC).
Regulatory Filing Details
| Item | Detail |
|---|---|
| Regulatory Agency | National Medical Products Administration (NMPA), China |
| Application Type | Supplemental New Drug Application |
| Proposed Indication | Perioperative treatment + adjuvant monotherapy for resectable Stage II–III NSCLC |
| Current Approved Indication | Resectable Stage IIIA–IIIB NSCLC |
| Expansion Scope | Broadens patient eligibility from Stage IIIA–IIIB to Stage II–III |
| Supporting Study | NEOTORCH study (NCT04158440) |
Clinical Evidence – NEOTORCH Study Results
The supplemental application is primarily supported by data from the NEOTORCH study (NCT04158440), which demonstrated compelling efficacy results announced in May 2026:
| Endpoint | Population | Result |
|---|---|---|
| Event-Free Survival (EFS) | Stage II–III | Met pre-specified superiority criteria |
| Major Pathological Response (MPR) Rate | Stage II–III | Met pre-specified superiority criteria |
| Major Pathological Response (MPR) Rate | Stage III | Met pre-specified superiority criteria |
The dual primary endpoints of EFS and MPR rates achieved statistical significance across both the broader Stage II–III population and the Stage III subgroup, validating the clinical benefit of the perioperative treatment approach.
Product Profile
- Product Name: Toripalimab injection (Loqtorzi)
- Class: Anti-PD-1 monoclonal antibody
- Significance: First domestic anti-PD-1 monoclonal antibody approved for marketing in China
- Treatment Regimen: Combination with platinum-containing chemotherapy in perioperative setting, followed by monotherapy as adjuvant therapy
- Target Population: Adult patients with resectable Stage II–III NSCLC
Global Development Pipeline
Junshi Biosciences has established a comprehensive global development program for toripalimab:
- Clinical Trials: Over 40 clinical trials initiated worldwide
- Geographic Reach: Studies conducted in China, United States, Europe, and Southeast Asia
- Indications: Coverage of more than 15 tumor types, including lung, nasopharyngeal, esophageal, gastric, bladder, breast, liver, kidney, and skin cancers
- Development Stage: Multiple ongoing or completed pivotal registration clinical trials
Market Impact
This indication expansion represents a significant opportunity to address a broader patient population in the early-stage NSCLC setting, where curative-intent surgery is possible but recurrence risk remains high. The perioperative treatment paradigm aims to improve long-term outcomes through immunotherapy intervention before and after surgical resection.
Strategic Significance
As China’s first domestically developed anti-PD-1 antibody, toripalimab continues to demonstrate its potential as a foundational immuno-oncology asset. The successful expansion into earlier disease stages aligns with global trends toward neoadjuvant and adjuvant immunotherapy approaches in solid tumors.
Forward‑Looking Statements
This brief contains forward-looking statements regarding regulatory approvals, clinical development, and commercial expectations. Actual results may differ due to risks including regulatory decisions, competitive dynamics, and market acceptance.-Fineline Info & Tech